Table 8 A summary of published clinical pharmacokinetics compared to the PK derived from the data with this study
From: Safety and pharmacokinetics of a highly bioavailable resveratrol preparation (JOTROL TM)
Paper | Dose form | Mean ± SD (or range where indicated) | Comment | |||
|---|---|---|---|---|---|---|
Cmax | Tmax | AUC (0-24) | t1/2 | |||
(ng/mL) | (h) | (ng*h/mL) | (h) | |||
Howells et al. (2011) | 5 g, SRT501, < 5 μm | 1942 ± 1422 | 2.8 ± 1.1 | 6327 ± 2247 | 1.1 ± 0.4 | |
la Porte et al. (2010) | 500 mg extract Transmax capsule, 2 g, standard breakfast | 1274 ± 790 | 3.0 to 4.5 | 3558 ± 2195 | 2.4 ± 1.4 | Low fat fed |
la Porte et al. (2010) | + breakfast, AUC to 12 h | 689 ± 345 | 4.5 to 5.0 | 1966 ± 643 | 2.5 ± 0.8 | High fat fed |
Brown et al. (2010) | 500 mg caplets, 5 g | 967 ± 517 | 0.5 to 1.5 | 4097 ± 4384 | 7.85 ± 1.97 | |
Boocock et al. (2007) | 500 mg caplets, 5 g, AUC to infinity | 538 ± 391 | 0.67 to 5.0 | 1319 ± 780 | 8.5 ± 8.2 | |
Pollack et al. (2017) | 1 g RevGenetics capsules (< 2.5 μm) | ~ 400 ± 1800 | 3 | nr | nr | Mixed meal |
Yiu et al. (2015) | 500 mg capsules, Mega Resveratrol, 2.5 g | 261 ± 242 | 1.5 | nr | nr | Low fat fed |
Turner et al. (2015) | 2 g, 500 mg encapsulated | 85 ± 184 | 1.5 | nr | 15 | |
Kemper (this manuscript) | 100 mg gelcaps, 200 mg JOTROLTM | 127 ± 116 | 1.0 | 149 ± 108 | 1.26 | Fasted |
100 mg gelcaps, 500 mg JOTROLTM | 455 ± 409 | 1.0 | 480 ± 256 | 2.7 | Fasted | |
100 mg gelcaps, 700 mg JOTROLTM | 805 ± 590 | 1.02 | 886 ± 456 | 1.6 | Fasted | |
100 mg gelcaps, 500 mg JOTROLTM | 205 ± 207 | 1.7 | 306 ± 201 | 1.7 | Fed | |
Walle et al. (2004) | 25 mg (overnight fast +3 h) | Cmax <5 ng/mL; total plasma radioactivity 491 ng/mL | ||||
Radiolabeled dose | Oral | IV | ||||
Urine | Feces | Urine | Feces | |||
70.5 ± 4.3 | 12.7 ± 6.1 | 64.1 ± 7.7 | 10.4 ± 3.7 | |||